查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
细胞和基因治疗药物输送设备市场 - 2018-2028 年全球行业规模、份额、趋势、机会和预测，按类型、商业化药物、给药途径、方法、地区和竞争细分
市场调查报告书
商品编码
1321036

细胞和基因治疗药物输送设备市场 - 2018-2028 年全球行业规模、份额、趋势、机会和预测，按类型、商业化药物、给药途径、方法、地区和竞争细分

Cell & Gene Therapy Drug Delivery Devices Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Type, By Commercialized Drugs, By Route of Administration, By Method, By Region and Competition
出版日期: | 出版商: TechSci Research | 英文 110 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球细胞和基因治疗药物输送设备市场预计将在 2024-2028 年预测期内呈现强劲增长。这可以归因于细胞和基因疗法越来越多地用于治疗癌症等各种慢性疾病。对在细胞和基因治疗过程中有效监测药物剂量的药物输送设备的需求不断增长，预计将支持未来几年的市场增长。

慢性病患病率增加

癌症在人群中的患病率以惊人的速度增长，以及对有效治疗的需求导致了各种细胞和基因疗法的发展。细胞和基因疗法的发展导致对用于递送它们的不同设备的需求增加，从而推动了全球细胞和基因治疗药物递送设备的增长。根据 Globocan 2020 的数据，全球报告了约 19,292,789 例新癌症病例。其中，男性新增癌症病例 10,065,305 例，其中最常见的癌症类型是肺癌、前列腺癌、结直肠癌、胃癌和肝癌。同样，女性人口中报告的新癌症病例数约为 9,227,484 例，其中乳腺癌、结直肠癌、肺癌、子宫颈癌和甲状腺癌是最常见的癌症。

FDA 越来越多地批准细胞和基因疗法及临床试验

随着第一个疗法于 2017 年获得批准，细胞疗法和基因疗法对于世界投资而言相对较新。据《细胞与基因杂誌》报导，FDA 批准的 22 种细胞和基因疗法中，有 14 种是基于脐带血的疗法。剩余的批准包括两种基因疗法、七种细胞疗法和五种改良细胞疗法。此外，总共 340 种已批准的生物製剂中，细胞和基因疗法仅占百分之七 (7%)。此外，在 FDA 2021 年批准的 50 多种药物中，只有 2 种是细胞或基因疗法。儘管这仅占 2021 年批准药物总数的一小部分，但这反映出批准的细胞和基因疗法增长了 10%，这是医学发展的显着一步。因此，越来越多的FDA批准提供更好的药物输送设备的最新产品在开髮用于输送细胞和基因疗法的设备的各公司中越来越受欢迎。反过来，预计这将在未来几年促进全球细胞和基因治疗药物输送设备市场的增长。

细胞和基因治疗市场的投资和资金增加

细胞治疗和基因治疗公司正在获得大量和比例的私人和公共投资。针对治疗效果不佳的疾病和慢性病的新型细胞和基因疗法的保证导致了大量资本从私人投资、首次公开募股和企业流出。随着生命科学领域私人投资的不断增长，细胞治疗和基因治疗投资的快速增长也是功不可没。据《Cell and Gene Journal》报导，基因治疗2010年至2021年的投资增长率已升至59%，而细胞治疗的投资率已增长至63%，这一数字值得期待，也值得期待。在预测期内为推动全球细胞和基因治疗药物输送设备市场的增长发挥了重要作用。

此外，多个国家的政府正在帮助提高患者和医生对该设备的认识，从而支持全球细胞和基因治疗药物输送设备市场的增长。

市场细分

全球细胞和基因治疗药物输送设备市场可以按类型、商业化药物、给药途径、方法和地区进行细分。根据类型，市场分为视网膜下注射插管、延长管、静脉导管、无菌胰岛素注射器、预充式註射器和输液袋。根据商业化药物，市场进一步细分为 Luxturna、Kymriah、Yescarta、Zolgensma、Provenge 和 Strimvelis。根据给药途径，市场进一步细分为口服、静脉注射、眼部、透皮等。根据方法的类型，市场可以分为体外和体外。从区域划分来看，市场分布在北美、欧洲、亚太、南美、中东和非洲。

市场参与者

Becton, Dickinson, and Company、诺华公司、安进公司、Kite Pharma, Inc.、辉瑞公司、博士伦公司、Bluebird bio, Inc.、Castle Creek Biosciences, Inc (Fibrocell Technologies, Inc.)、Dendreon Pharmaceuticals LLC. 、Helixmith Co., Ltd (ViroMed Co., Ltd)、Orchard Therapeutics plc、Renova Therapeutics、Spark Therapeutics, Inc.、uniQure NV、Vericel Corporation 是全球细胞和基因治疗领域的一些领先参与者药物输送装置市场。

可用的定制

根据给定的市场数据，TechSci Research 可根据公司的具体需求提供定制服务。该报告可以使用以下自定义选项：

公司信息

  • 其他市场参与者（最多五个）的详细分析和概况分析。

目录

第 1 章：产品概述

  • 市场定义
  • 市场范围
    • 涵盖的市场
    • 考虑学习的年份
    • 主要市场细分

第 2 章：研究方法

  • 研究目的
  • 基线方法
  • 主要行业合作伙伴
  • 主要协会和二手资料来源
  • 预测方法
  • 数据三角测量和验证
  • 假设和限制

第 3 章：执行摘要

  • 市场概况
  • 主要市场细分概述
  • 主要市场参与者概述
  • 重点地区/国家概况
  • 市场驱动因素、挑战、趋势概述

第 4 章：客户之声

第 5 章：临床试验分析

  • 正在进行的临床试验
  • 已完成的临床试验
  • 终止的临床试验
  • 按开发阶段分類的管道细目
  • 管道细分（按状态）
  • 按研究类型分類的管道细目
  • 按地区分類的管道明细
  • 临床试验热图

第 6 章：全球细胞和基因治疗药物输送设备市场展望

  • 市场规模及预测
    • 按价值
  • 市场份额及预测
    • 按类型（视网膜下注射插管、延长管、静脉导管、无菌胰岛素注射器、预充式註射器、输液袋）
    • 按商业化药物分类（Luxturna、Kymriah、Yescarta、Zolgensma、Provenge、Strimvelis）
    • 按给药途径（口服、静脉注射、眼部、透皮、其他）
    • 按方法分类（体外与体外）
    • 按公司划分 (2022)
    • 按地区
  • 市场地图
    • 按类型
    • 按商业化药物
    • 按给药途径
    • 按方法
    • 按地区

第 7 章：亚太地区细胞和基因治疗药物输送设备市场展望

  • 市场规模及预测
    • 按价值
  • 市场份额及预测
    • 按类型（视网膜下注射插管、延长管、静脉导管、无菌胰岛素注射器、预充式註射器、输液袋）
    • 按商业化药物分类（Luxturna、Kymriah、Yescarta、Zolgensma、Provenge、Strimvelis）
    • 按给药途径（口服、静脉注射、眼部、透皮、其他）
    • 按方法分类（体外与体外）
    • 按国家/地区
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳大利亚

第 8 章：欧洲细胞和基因治疗药物输送设备市场展望

  • 市场规模及预测
    • 按价值
  • 市场份额及预测
    • 按类型（视网膜下注射插管、延长管、静脉导管、无菌胰岛素注射器、预充式註射器、输液袋）
    • 按商业化药物分类（Luxturna、Kymriah、Yescarta、Zolgensma、Provenge、Strimvelis）
    • 按给药途径（口服、静脉注射、眼部、透皮、其他）
    • 按方法分类（体外与体外）
    • 按国家/地区
  • 欧洲：国家分析
    • 法国
    • 德国
    • 英国
    • 意大利
    • 西班牙

第 9 章：北美细胞和基因治疗药物输送设备市场展望

  • 市场规模及预测
    • 按价值
  • 市场份额及预测
    • 按类型（视网膜下注射插管、延长管、静脉导管、无菌胰岛素注射器、预充式註射器、输液袋）
    • 按商业化药物分类（Luxturna、Kymriah、Yescarta、Zolgensma、Provenge、Strimvelis）
    • 按给药途径（口服、静脉注射、眼部、透皮、其他）
    • 按方法分类（体外与体外）
    • 按国家/地区
  • 北美：国家分析
    • 美国
    • 墨西哥
    • 加拿大

第 10 章：南美细胞和基因治疗药物输送设备市场展望

  • 市场规模及预测
    • 按价值
  • 市场份额及预测
    • 按类型（视网膜下注射插管、延长管、静脉导管、无菌胰岛素注射器、预充式註射器、输液袋）
    • 按商业化药物分类（Luxturna、Kymriah、Yescarta、Zolgensma、Provenge、Strimvelis）
    • 按给药途径（口服、静脉注射、眼部、透皮、其他）
    • 按方法分类（体外与体外）
    • 按国家/地区
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 11 章：中东和非洲细胞和基因治疗药物输送设备市场展望

  • 市场规模及预测
    • 按价值
  • 市场份额及预测
    • 按类型（视网膜下注射插管、延长管、静脉导管、无菌胰岛素注射器、预充式註射器、输液袋）
    • 按商业化药物分类（Luxturna、Kymriah、Yescarta、Zolgensma、Provenge、Strimvelis）
    • 按给药途径（口服、静脉注射、眼部、透皮、其他）
    • 按方法分类（体外与体外）
    • 按国家/地区
  • MEA：国家分析
    • 南非细胞和基因治疗药物输送设备
    • 沙特阿拉伯细胞和基因治疗药物输送设备
    • 阿联酋细胞和基因治疗药物输送设备

第 12 章：市场动态

  • 司机
  • 挑战

第 13 章：市场趋势与发展

  • 最近的发展
  • 併购
  • 产品发布

第14章：竞争格局

  • 商业概览
  • 公司概况
  • 产品与服务
  • 财务（据报导）
  • 最近的发展
  • SWOT分析
    • Becton, Dickinson, and Company
    • Novartis AG
    • Amgen Inc.
    • Kite Pharma, Inc.
    • Pfizer, Inc.
    • Bausch & Lomb Incorporated
    • Bluebird bio, Inc.
    • Castle Creek Biosciences, Inc (Fibrocell Technologies, Inc.)
    • Dendreon Pharmaceuticals LLC.
    • Helixmith Co., Ltd (ViroMed Co., Ltd)

第 15 章：战略建议

简介目录
Product Code: 7364

Global Cell & Gene Therapy Drug Delivery Devices market is expected to show robust growth in the forecast period, 2024-2028. This can be attributed to the growing use of cell and gene therapy for the treatment of various chronic diseases such as cancer. The increasing demand for drug delivery devices that are efficient in monitoring drug dosage during cell and gene therapies is expected to support market growth in the coming years.

Cell and Gene Therapy is a transformative industry that is emerging with efficient potential. Cell and Gene therapy includes the extraction of cells, proteins, or genetic material (DNA) from the Donor and altering them to provide highly specific and personalized therapy. The growing popularity of personalized medicine has significantly increased the demand for cell and gene therapies, thereby creating the demand for devices used to deliver these therapies.

The effective dosages help in maximizing the bioavailability of the drug at the target sites, making it convenient for the patients and thereby actively supporting the growth of devices used for delivering different therapies, including cell and gene therapies, in the coming years. Novel drug delivery systems like subdermal implants available in the market as variants such as rings and patches are anticipated to boost the global cell & gene therapy drug delivery devices market growth in the forecast period.

Increasing Prevalence of Chronic Diseases

The growing prevalence of cancer among the population at an alarming rate and the requirement for an effective treatment has led to the development of various cell and gene therapies. The development of cell and gene therapies has led to an increase in demand for different devices used to deliver them, thereby driving the growth of global cell and gene therapy drug delivery devices. According to the Globocan 2020, there are around 19,292,789 new cases of cancer reported among the population across the globe. Out of these, 10,065,305 new cancer cases were reported among males, and the most common type of cancer among them was Lung, Prostate, Colorectum, Stomach, and Liver cancer. Similarly, the number of new cancer cases reported in the female population was around 9,227,484, with breast cancer, colorectum cancer, lung cancer, cervix uteri, and thyroid cancer being the most prevalent ones.

A growing number of FDA approvals regarding Cell and Gene Therapies & Clinical Trials

With the first therapy approved in 2017, Cell therapies & Gene therapies are relatively new to the world for investments. According to the Cell and Gene Journal, out of 22 cell and gene therapies approved by the FDA, 14 are cord blood-based treatments. The remaining approvals include two gene therapies, seven cell therapies, and five modified cell therapies. Also, in total, cell & gene therapies account for just seven percent (7%) of the total 340 approved biologics. Also, of the over 50 total drugs approved by the FDA in 2021, only 2 were cell or gene therapies. Though it's a small amount of the total approved drugs in 2021, it reflects that the approved cell and gene therapies grew by 10%, which is a remarkable step in the development of medicine. Thus, the growing number of FDA approvals for the latest launches providing better drug delivery devices are gaining popularity among various companies for the development of devices used for delivering cell and gene therapies. This, in turn, is expected to bolster the growth of global cell & gene therapy drug delivery devices market in the coming years.

Increased Investment and Funding in the Cell and Gene Therapy Market

The Cell therapy & Gene therapy companies are getting an excellent amount & proportion of private and public investment. The assurance of novel cell and gene therapies which are targeting poorly treated diseases and chronic conditions has led to substantial capital flowing from private investments, initial public offerings, and corporates. With the growing private investment in life sciences, the rapid growth in investment in cell therapy and gene therapy is accountable. According to the Cell and Gene Journal, for gene therapy, the investment growth rate from 2010 to 2021 has risen to 59%, whereas for cell therapy, the investment rate has grown to 63%, which is accountable on a higher note and also anticipated for bringing a significant role in boosting the Global Cell & Gene Therapy Drug Delivery Devices Market growth during the forecast period.

Also, the various Government of several countries is aiding the process of increasing awareness about the devices among patients and doctors, thereby supporting the Global Cell & Gene Therapy Drug Delivery Devices market growth.

Market Segmentation

Global Cell & Gene Therapy Drug Delivery Devices Market can be segmented by type, commercialized drugs, route of administration, method, and region. Based on type, the market is fragmented into subretinal injection cannulas, extension tubes, intravenous catheters, sterile insulin syringes, prefilled syringe, and infusion bags. Based on the Commercialized Drugs, the market is further segmented into Luxturna, Kymriah, Yescarta, Zolgensma, Provenge, and Strimvelis. Depending on the Route of Administration, the market is further segmented into Oral, Intravenous, Ocular, Transdermal, and Others. Based on the type of method, the market can be segmented into In Vitro and Ex Vivo. Based on the regional segmentation, the market is distributed among North America, Europe, Asia- Pacific, South America, and Middle East and Africa.

Market Players

Becton, Dickinson, and Company, Novartis AG, Amgen Inc., Kite Pharma, Inc., Pfizer, Inc., Bausch & Lomb Incorporated, Bluebird bio, Inc., Castle Creek Biosciences, Inc (Fibrocell Technologies, Inc.), Dendreon Pharmaceuticals LLC., Helixmith Co., Ltd (ViroMed Co., Ltd), Orchard Therapeutics plc, Renova Therapeutics, Spark Therapeutics, Inc., uniQure N.V., Vericel Corporation, are some of the leading players operating in the global cell & gene therapy drug delivery devices market.

Report Scope

In this report, global cell & gene therapy drug delivery devices market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Cell & Gene Therapy Drug Delivery Devices Market, By Type:

  • Subretinal Injection Cannula
  • Extension Tube
  • Intravenous Catheter
  • Sterile Insulin Syringe
  • Prefilled Syringe
  • Infusion Bags

Cell & Gene Therapy Drug Delivery Devices Market, By Commercialized Drugs:

  • Luxturna
  • Kymriah
  • Yescarta
  • Zolgensma
  • Provenge
  • Strimvelis

Cell & Gene Therapy Drug Delivery Devices Market, By Route of Administration:

  • Oral
  • Intravenous
  • Ocular
  • Transdermal
  • Others

Cell & Gene Therapy Drug Delivery Devices Market, By Method:

  • In Vitro
  • Ex Vivo

Cell & Gene Therapy Drug Delivery Devices Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
  • South America
    • Brazil
    • Argentina
    • Colombia

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global Cell & Gene Therapy Drug Delivery Devices market.

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Clinical Trial Analysis

  • 5.1. Ongoing Clinical Trials
  • 5.2. Completed Clinical Trials
  • 5.3. Terminated Clinical Trials
  • 5.4. Breakdown of Pipeline, By Development Phase
  • 5.5. Breakdown of Pipeline, By Status
  • 5.6. Breakdown of Pipeline, By Study Type
  • 5.7. Breakdown of Pipeline, By Region
  • 5.8. Clinical Trials Heat Map

6. Global Cell & Gene Therapy Drug Delivery Devices Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type (Subretinal Injection Cannula, Extension Tube, Intravenous Catheter, Sterile Insulin Syringe, Prefilled Syringe, Infusion Bags)
    • 6.2.2. By Commercialized Drugs (Luxturna, Kymriah, Yescarta, Zolgensma, Provenge, Strimvelis)
    • 6.2.3. By Route of Administration (Oral, Intravenous, Ocular, Transdermal, Others)
    • 6.2.4. By Method (In Vitro v/s Ex Vivo)
    • 6.2.5. By Company (2022)
    • 6.2.6. By Region
  • 6.3. Market Map
    • 6.3.1. By Type
    • 6.3.2. By Commercialized Drugs
    • 6.3.3. By Route of Administration
    • 6.3.4. By Method
    • 6.3.5. By Region

7. Asia-Pacific Cell & Gene Therapy Drug Delivery Devices Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type (Subretinal Injection Cannula, Extension Tube, Intravenous Catheter, Sterile Insulin Syringe, Prefilled Syringe, Infusion Bags)
    • 7.2.2. By Commercialized Drugs (Luxturna, Kymriah, Yescarta, Zolgensma, Provenge, Strimvelis)
    • 7.2.3. By Route of Administration (Oral, Intravenous, Ocular, Transdermal, Others)
    • 7.2.4. By Method (In Vitro v/s Ex Vivo)
    • 7.2.5. By Country
  • 7.3. Asia-Pacific: Country Analysis
    • 7.3.1. China Cell & Gene Therapy Drug Delivery Devices Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Commercialized Drugs
        • 7.3.1.2.3. By Route of Administration
        • 7.3.1.2.4. By Method
    • 7.3.2. India Cell & Gene Therapy Drug Delivery Devices Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Commercialized Drugs
        • 7.3.2.2.3. By Route of Administration
        • 7.3.2.2.4. By Method
    • 7.3.3. South Korea Cell & Gene Therapy Drug Delivery Devices Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Commercialized Drugs
        • 7.3.3.2.3. By Route of Administration
        • 7.3.3.2.4. By Method
    • 7.3.4. Japan Cell & Gene Therapy Drug Delivery Devices Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Commercialized Drugs
        • 7.3.4.2.3. By Route of Administration
        • 7.3.4.2.4. By Method
    • 7.3.5. Australia Cell & Gene Therapy Drug Delivery Devices Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Commercialized Drugs
        • 7.3.5.2.3. By Route of Administration
        • 7.3.5.2.4. By Method

8. Europe Cell & Gene Therapy Drug Delivery Devices Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type (Subretinal Injection Cannula, Extension Tube, Intravenous Catheter, Sterile Insulin Syringe, Prefilled Syringe, Infusion Bags)
    • 8.2.2. By Commercialized Drugs (Luxturna, Kymriah, Yescarta, Zolgensma, Provenge, Strimvelis)
    • 8.2.3. By Route of Administration (Oral, Intravenous, Ocular, Transdermal, Others)
    • 8.2.4. By Method (In Vitro v/s Ex Vivo)
    • 8.2.5. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Cell & Gene Therapy Drug Delivery Devices Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Commercialized Drugs
        • 8.3.1.2.3. By Route of Administration
        • 8.3.1.2.4. By Method
    • 8.3.2. Germany Cell & Gene Therapy Drug Delivery Devices Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Commercialized Drugs
        • 8.3.2.2.3. By Route of Administration
        • 8.3.2.2.4. By Method
    • 8.3.3. United Kingdom Cell & Gene Therapy Drug Delivery Devices Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Commercialized Drugs
        • 8.3.3.2.3. By Route of Administration
        • 8.3.3.2.4. By Method
    • 8.3.4. Italy Cell & Gene Therapy Drug Delivery Devices Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Commercialized Drugs
        • 8.3.4.2.3. By Route of Administration
        • 8.3.4.2.4. By Method
    • 8.3.5. Spain Cell & Gene Therapy Drug Delivery Devices Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Commercialized Drugs
        • 8.3.5.2.3. By Route of Administration
        • 8.3.5.2.4. By Method

9. North America Cell & Gene Therapy Drug Delivery Devices Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type (Subretinal Injection Cannula, Extension Tube, Intravenous Catheter, Sterile Insulin Syringe, Prefilled Syringe, Infusion Bags)
    • 9.2.2. By Commercialized Drugs (Luxturna, Kymriah, Yescarta, Zolgensma, Provenge, Strimvelis)
    • 9.2.3. By Route of Administration (Oral, Intravenous, Ocular, Transdermal, Others)
    • 9.2.4. By Method (In Vitro v/s Ex Vivo)
    • 9.2.5. By Country
  • 9.3. North America: Country Analysis
    • 9.3.1. United States Cell & Gene Therapy Drug Delivery Devices Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Commercialized Drugs
        • 9.3.1.2.3. By Route of Administration
        • 9.3.1.2.4. By Method
    • 9.3.2. Mexico Cell & Gene Therapy Drug Delivery Devices Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Commercialized Drugs
        • 9.3.2.2.3. By Route of Administration
        • 9.3.2.2.4. By Method
    • 9.3.3. Canada Cell & Gene Therapy Drug Delivery Devices Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Commercialized Drugs
        • 9.3.3.2.3. By Route of Administration
        • 9.3.3.2.4. By Method

10. South America Cell & Gene Therapy Drug Delivery Devices Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type (Subretinal Injection Cannula, Extension Tube, Intravenous Catheter, Sterile Insulin Syringe, Prefilled Syringe, Infusion Bags)
    • 10.2.2. By Commercialized Drugs (Luxturna, Kymriah, Yescarta, Zolgensma, Provenge, Strimvelis)
    • 10.2.3. By Route of Administration (Oral, Intravenous, Ocular, Transdermal, Others)
    • 10.2.4. By Method (In Vitro v/s Ex Vivo)
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Cell & Gene Therapy Drug Delivery Devices Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Commercialized Drugs
        • 10.3.1.2.3. By Route of Administration
        • 10.3.1.2.4. By Method
    • 10.3.2. Argentina Cell & Gene Therapy Drug Delivery Devices Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Commercialized Drugs
        • 10.3.2.2.3. By Route of Administration
        • 10.3.2.2.4. By Method
    • 10.3.3. Colombia Cell & Gene Therapy Drug Delivery Devices Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Commercialized Drugs
        • 10.3.3.2.3. By Route of Administration
        • 10.3.3.2.4. By Method

11. Middle East and Africa Cell & Gene Therapy Drug Delivery Devices Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Type (Subretinal Injection Cannula, Extension Tube, Intravenous Catheter, Sterile Insulin Syringe, Prefilled Syringe, Infusion Bags)
    • 11.2.2. By Commercialized Drugs (Luxturna, Kymriah, Yescarta, Zolgensma, Provenge, Strimvelis)
    • 11.2.3. By Route of Administration (Oral, Intravenous, Ocular, Transdermal, Others)
    • 11.2.4. By Method (In Vitro v/s Ex Vivo)
    • 11.2.5. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Cell & Gene Therapy Drug Delivery Devices Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Type
        • 11.3.1.2.2. By Commercialized Drugs
        • 11.3.1.2.3. By Route of Administration
        • 11.3.1.2.4. By Method
    • 11.3.2. Saudi Arabia Cell & Gene Therapy Drug Delivery Devices Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Type
        • 11.3.2.2.2. By Commercialized Drugs
        • 11.3.2.2.3. By Route of Administration
        • 11.3.2.2.4. By Method
    • 11.3.3. UAE Cell & Gene Therapy Drug Delivery Devices Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Type
        • 11.3.3.2.2. By Commercialized Drugs
        • 11.3.3.2.3. By Route of Administration
        • 11.3.3.2.4. By Method

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

  • 13.1. Recent Developments
  • 13.2. Mergers & Acquisitions
  • 13.3. Product Launches

14. Competitive Landscape

  • 14.1. Business Overview
  • 14.2. Company Snapshot
  • 14.3. Products & Services
  • 14.4. Financials (As Reported)
  • 14.5. Recent Developments
  • 14.6. SWOT Analysis
    • 14.6.1. Becton, Dickinson, and Company
    • 14.6.2. Novartis AG
    • 14.6.3. Amgen Inc.
    • 14.6.4. Kite Pharma, Inc.
    • 14.6.5. Pfizer, Inc.
    • 14.6.6. Bausch & Lomb Incorporated
    • 14.6.7. Bluebird bio, Inc.
    • 14.6.8. Castle Creek Biosciences, Inc (Fibrocell Technologies, Inc.)
    • 14.6.9. Dendreon Pharmaceuticals LLC.
    • 14.6.10. Helixmith Co., Ltd (ViroMed Co., Ltd)

15. Strategic Recommendations